Live Geos: https://partners.subjectwell.com/publishers/geos_report/d2d653f9-64e6-44a2-895e-c74644b9944d **ALL COPY AND CREATIVE MUST BE SENT TO [email protected] PRIOR TO GOING LIVE FOR APPROVAL** Ages: 18+ Gender: Any Study Description: This study is testing the safety and effectiveness of an investigational oral medication for Type II Diabetes. Participants will receive either the investigational medication, its matching placebo, or a commercially available alternative, Semaglutide, for 26 weeks. Additional procedures will include vital signs, physical examinations, and questionnaires. Total participation will last approximately 7 months and would include 16 doctor’s visits throughout the study. Eligibility for the study will be determined by the study doctor following one or more in-person screening visits to the clinic. Trial-related procedures and study medication will be provided at no cost. QUESTIONS/ANSWERS - DO NOT GIVE TO USER: 1. Have you been diagnosed with Type II Diabetes for at least 6 months? - YES 2. What was your most recent HbA1c value? A. Less than 6.9% B. 7.0% - 10.5% C. Greater than 10.5% D. Unsure - B OR D 3. Have you been taking insulin in the last 12 months? - NO 4. In the last 3 months, have you taken any of the following medications? - Semaglutide (Rybelsus) - Acarbose (Precose) - Miglitol (Glyset) - Sitagliptin (Januvia) - Saxagliptin (Onglyza) - Repaglinide (Prandin) - NO 5. In the last 3 months, have you taken any of the following GLP-1 medications for weight loss or Type 2 Diabetes? Examples include: Exenatide (Byetta, Bydureon), Liraglutide (Victoza, Saxenda), Albiglutide (Tanzeum), Dulaglutide (Trulicity), Lixisenatide (Adlyxin), Semaglutide (Ozempic, Rybelsus, Wegovy), Tirzepatide (Zepbound, Mounjaro) , - NO

ClicksAdv, LLC